Vicore Pharma Holding ABOMXSTO: VICO

Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum

· Issued by Vicore Pharma Holding AB via ACCESS Newswire

Summary by 6ix AI

Vicore Pharma Holding AB, a clinical-stage drug developer working on a new class of drugs called angiotensin II type 2 receptor agonists, will take part in the Stifel 2026 Virtual Immunology and Inflammation Forum with a presentation and one-on-one meetings.

Key details

  • The presentation is scheduled for Thursday, September 24, 2026, 8:30-8:55 AM ET, in a virtual format, with a webcast.
  • Participants are Ahmed Mousa, CEO; Hans Jeppsson, CFO; and Bernt van den Blink, CMO (chief medical officer).

6ix AI wrote this summary from the release below and checked it against the release.

STOCKHOLM, SE / ACCESS Newswire / September 17, 2026 / Vicore Pharma Holding AB (publ) (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists, today announced that the company will participate in the Stifel 2026 Virtual Immunology and Inflammation Forum.

Location: Virtual

Format: Presentation and 1×1 meetings

Presentation Date and Time: Thursday, September 24, 2026, 8:30-8:55 AM ET

Participants: Ahmed Mousa, CEO; Hans Jeppsson, CFO; and Bernt van den Blink, CMO

Webcast: Link

For more information, please contact:

Hans Jeppsson, CFO, +46 70 553 14 65, [email protected]

About Vicore Pharma
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com

Attachments
Vicore Pharma to Present in the Stifel 2026 Virtual Immunology and Inflammation Forum

SOURCE: Vicore Pharma Holding

View the original press release on ACCESS Newswire

View original source (ACCESS Newswire)Vicore Pharma Holding AB on 6ix

Story so far

Earlier from Vicore Pharma

All Vicore Pharma news releases